Drug Trial Radar · NCT04693234
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
178
Actual
Start
Feb 15, 2021
Primary completion
Jun 16, 2022
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jan 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.
Conditions
- Cervical Cancer
Interventions
TislelizumabBiological
200 mg administered intravenously once every 3 weeks on day 1 of each cycle
OciperlimabBiological
900 mg administered intravenously once every 3 weeks on day 1 of each cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive ParticipantsTime frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
- Cohort 1: ORR Assessed by the IRC in All Treated ParticipantsTime frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
Locations
68 sites in 8 countries. Site status is shown where the registry gives one.
"Mhat uni hospital" ood
Panagyurishte, Bulgaria
Complex Oncology Center Rousse Eood
Rousse, Bulgaria
Medical center nadezhda clinical eood
Sofia, Bulgaria
Acibadem city clinic tokuda umhat ead, department of medical oncology
Sofia, Bulgaria
Beijing Cancer Hosptial
Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Linyi Cancer Hospital
Shandong, China
The First Affiliated Hospital of Xiamen University - Oncology
Xiamen, China
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Southwest Hospital
Chongqing, Chongqing Municipality, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
Sun yat-sen memorial hospital, sun yat-sen university (south)
Guanzhou, Guangdong, China
The Tumor Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi, China
Hainan Cancer Hospital
Haikou, Hainan, China
Henan Cancer Hospital - Oncology
Zhengzhou, Henan, China
Hubei Cancer Hospital - Oncology
Wuhan, Hubei, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital - GCP Office
Changsha, Hunan, China
Xuzhou Cancer Hospital
Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China
Jilin Guowen Hospital
Jilin City, Jilin, China
Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology
Shenyang, Liaoning, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Second Hospital Of Shanxi Medical University
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Tianjin Medical University Cancer institute & Hospital
Tianjin, Tianjin Municipality, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Szpitale Pomorskie Spółka z ograniczoną odpowiedzialnością
Gdynia, Poland
Przychodnia lekarska komed
Konin, Poland
Arkhangelsk regional clinical oncological dispensary
Arkhangelsk, Russia
State budgetary healthcare institution-chelyabinsk regional clinical center of oncology and nuclear
Chelyabinsk, Russia
State healthcare institution oncologic dispensary no. 2 - health department of krasnodar region
Krasnodar, Krasnodarskiy Kray, Russia
Fsbi of higher education"ogarev mordovia state university"
Saransk, Mordovia Republic, Russia
Oncological Scientific Center LLC
Pesochny, Sankt-Peterburg, Russia
Sbhi of stavropol region "pyatigorsk interdistrict oncologic dispensary"
Pyatigorsk, Stavropol Kray, Russia
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.